TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase 1 testing, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.
Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase 1 testing, that is being developed through a collaboration with I-Mab Biopharma; multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma.
Services
Eucure Biopharma, a subsidiary of Biocytogen, is a China based innovative biotechnology company with global vision, specializing in developing innovative antibody drugs with independent intellectual property rights. Relying on a strong clinical development team with extensive experience, the company has established a product pipeline for more than 10 targets.
At TRACON, you will find a team of individuals committed to improving the lives of patients with cancer and other diseases of high unmet medical need. If you are motivated, dedicated and share our passion for developing novel therapies, and thrive in a rapidly changing environment, then TRACON may be the right place for you.
Reviews
Be the first to review TRACON Pharmaceuticals.
Write a Review
